Abdul Abdirahman
Principal
F-Prime
Principal investing in early-stage B2B software, fintech, and vertical SaaS.
Bio
Professional summary
Stephen Knight is President and Senior Managing Partner at F-Prime Capital, based in Cambridge. He joined the firm in 2003 and invests broadly across healthcare after more than 30 years in the pharmaceutical and biotechnology industries. His official profile lists board roles at Atalanta Therapeutics, Leyden Labs, Paradigm, Quarry Thera, and Xaira Therapeutics, as well as past involvement with many public and acquired healthcare companies. Before F-Prime, he held senior management roles in biotechnology and consulting and conducted research at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an MD and MBA from Yale and a BS in biology from Columbia University.
Investment focus
Stage, sector, and overall fit
Stage
Healthcare venture investments across stages
Sector
HealthcarePharmaceuticalsBiotechnologyTherapeuticsGene editing and precision medicine
Thesis
Broad healthcare investingPharmaceuticals and biotechnology
Notable companies
Selected portfolio companies the partner has backed
Atalanta TherapeuticsLeyden LabsParadigmQuarry TheraXaira TherapeuticsBeam TherapeuticsBlueprint MedicinesDenali TherapeuticsFoldRx PharmaceuticalsInnovent BiologicsIora HealthIronwood PharmaceuticalsPrime MedicineSana BiotechnologySemma TherapeuticsVerve Therapeutics
How to approach
Framing and angles for outreach
Pitch framing
Lead with rigorous healthcare science, strong clinical or translational rationale, and a path to meaningful patient impact.
Personalization hooks
- 1Reference his combination of MD/MBA training, biotech operating experience, and broad healthcare investing.
- 2If relevant, connect to gene editing, therapeutics, biotechnology platforms, or healthcare AI, based on portfolio overlap.
Background
Career, education, and skills
Career history
- F-Prime Capital (formerly Fidelity Biosciences)President & Senior Managing Partner2003 - Present
- AT&T Bell LaboratoriesResearcherPre-2003
- National Institutes of Health (NIH)ResearcherPre-2003
- Yale UniversityResearcherPre-2003
Education
- Yale University School of MedicineMD
- Yale School of Organization and ManagementMBA
- Columbia UniversityBS, Biology (summa cum laude, Phi Beta Kappa)
Other partners at F-Prime
12 more profiles
Alex Pasteur
Partner
F-Prime
Alex Pasteur is a London-based Partner at F-Prime Capital focused on therapeutics and life sciences.
AP
Anastasiya Sybirna, PhD
Senior Associate
F-Prime
Senior Associate on F-Prime's London healthcare investment team.
Bala Varadhan
Principal
F-Prime
Principal focused on early-stage crypto, blockchain and Web3 investments.
Benjamin Gorman
Principal
F-Prime
Principal investing in early-stage enterprise software and AI.
Betsy Mulé
Principal
F-Prime
Principal investing in enterprise technology and robotics.
Brett Cook
Partner
F-Prime
F-Prime Partner investing in healthcare technology and services companies.
Brian Yordy
Principal
F-Prime
Principal investing in biopharmaceutical and medical technology companies.
Carl Bradford Byers 🚑
Partner
F-Prime
F-Prime Partner and former athenahealth founding CFO investing in healthcare IT and digital health.
Carl Byers
Partner
F-Prime
Carl Byers is a Partner at F-Prime Capital with significant operating experience in healthcare IT, including as a founding team member and CFO of athenahealth.
Chance Mathisen
Associate
F-Prime
Associate focused on early-stage enterprise software investments.
Chong Xu
Partner
F-Prime
F-Prime partner focused on biopharma, medtech, company formation, and China healthcare opportunities.